Home › Compare › SEGYY vs ABBV
SEGYY yields 577.70% · ABBV yields 3.06%● Live data
📍 SEGYY pulled ahead of the other in Year 1
Combined, SEGYY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SEGYY + ABBV for your $10,000?
SPT Energy Group Inc., an investment holding company, provides integrated oilfield services; and manufactures and sells oilfield services related products in the People's Republic of China, Kazakhstan, Turkmenistan, Canada, Singapore, Indonesia, the Middle East, and internationally. It operates through three segments: Drilling, Well Completion, and Reservoir. The company offers drilling services, including drilling rig, workover rig, complex well workover and fishing, cementing and drilling fluid services, etc., as well as rotary geosteering, vertical drilling, horizontal drilling, side tracking, underbalanced drilling, and fine managed pressure drilling technology services. It also provides well completion project design, well completion tools, and stimulation and fracturing services. In addition, the company offers geology research and oil reservoir research, dynamic monitoring, oil testing and recovery technology, coiled tubing service, and repair service of surface production devices, etc. Further, it is also involved in farming, trading, and manufacturing activities; the promotion of technology and application services; and the provision of gas operation and services. SPT Energy Group Inc. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Full SEGYY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.